Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Kochenderfer JN et al. Proc ASH 2013;Abstract 168.

Advertisements

Patrick Stiff MD Coleman Professor of Oncology

Basic Immunology of the Mouse (and Human) Nicholas P. Restifo, MD October 19, 2015.

The Role of Immunotherapy for the Treatment of Hematologic Malignancies Patrick Stiff MD Coleman Professor of Oncology Loyola University Medical Center.

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

chimeric antigen receptor T-cell therapy for ALL

Professor John Gribben Barts Cancer Institute

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Immunotherapy for lymphoma: The time is now

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Discussion Outline Cells of the Immune System.

Figure 2 Multiscale modelling in oncology

Figure 1 Generations of cancer vaccine antigens

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Research Techniques Made Simple: CAR T-Cell Therapy

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 1 Clinical case study

Nat. Rev. Urol. doi: /nrurol

Figure 4 Macrophage-targeting antitumour treatment approaches

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 3 Drug cycling with collateral sensitivity

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Rheumatol. doi: /nrrheum

Daniel Abate-Daga, Marco L Davila Molecular Therapy - Oncolytics

Figure 1 Balance between proteasomal load and capacity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 3 The yin and yang of tumour-associated

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

CAR-T cells: New HOPE FOR CANCER PATIENTS

Figure 2 Approaches to improve CAR-T-cell therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Dominance of the cell-extrinsic effects of autophagy

Figure 2 Frequency and overlap of alterations

Figure 2 Logistical requirements for autologous

Research Techniques Made Simple: CAR T-Cell Therapy

Figure 3 Tumours secrete factors that cause systemic immunosuppression

The Pharmacology of T Cell Therapies

Figure 1 Mechanisms of action of immunotherapy modalities

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 3 Determination of the primary site

Toxicity and management in CAR T-cell therapy

Figure 4 Molecular signalling and immunological

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.128 Figure 2 Different approaches to improving chimeric antigen receptor (CAR)‑T‑cell therapies Figure 2 | Different approaches to improving chimeric antigen receptor (CAR)‑T‑cell therapies. Strategies aimed at improving the safety and effectiveness of CAR‑T‑cell therapies are focused on multiple steps in the overall process of manufacturing and administering these treatments. Modifications of all aspects of CAR design are being pursued, in order to reduce antigenicity or improve signalling capacity. Incorporation of additional genes into the expression vector construct, such as genes encoding chemoattractants or ‘suicide genes’, might enhance CAR‑T‑cell activity or enable greater control of toxicities. Changes to cell-culture methods can also be used to generate CAR‑T‑cell products with cellular phenotypes associated with enhanced antitumour immune responses. With regard to administration of treatment, optimization of conditioning regimens will improve patient outcomes. Furthermore, the addition of post-infusion pharmacological agents, such as immune-checkpoint inhibitors, stimulatory cytokines, or inhibitors of B‑cell signalling, might enhance the activity of, or synergize with, CAR T cells to improve the effectiveness of therapy. Brudno, J. N. & Kochenderfer, J. N. (2017) Chimeric antigen receptor T‑cell therapies for lymphoma Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.128